

LDN: A Game Changer for Many Patients

By Pamela W. Smith, MD, MPH, MS

Complete References



1. Li, Z., et al., “Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy,” *Int Immunopharmacol* 2018; 61:178-84.
2. Strazzulla, L., et al., “Novel treatment using low-dose naltrexone for lichen planopilaris,” *Jour Drugs Derm* 2017; 16(11):1140-42.
3. Bihari, B., “Low-dose naltrexone for normalizing immune system function,” *Altern Ther Health Med* 2013; 19(2):56–65.
4. Kim, P., et al., “Low-dose naltrexone for chronic pain: Update and systemic review,” *Curr Pain Headache Rep* 2020; 24(10):64.
5. Patten, D., et al., “The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease and other pain disorders,” *Pharmacotherapy* 2018; 38(3):382-89.
6. Smith, J., et al., “Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial,” *Dig Dis Sci* 2011; 56(7):2088–97.
7. Smith, J., et al., “Low-dose naltrexone therapy improves active Crohn’s disease,” *Amer Jour Gastroenterol* 2007; 102(4):820–28.
8. Smith, J., et al., “Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study,” *Jour Clin Gastroenterol* 2013; 47(4):339–45.
9. Lie, M., et al., “Low dose naltrexone for induction of remission in inflammatory bowel disease patients,” *Jour Transl Med* 2018; 16(1):55.
10. Cree, B., et al., “Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis,” *Ann Neurol* 2010; 68(2):145–50.
11. Sharafaddinzadeh, N., et al., “The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial,” *Mult Scler* 2010; 16(8):964–69.
12. Ludwig, M., et al., “Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone,” *Exp Biol Med* 2017; 242(15):1524–33.
13. Raknes, C., et al., “Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study,” *PLoS One* 2019; 14(2):e0212460.
14. Cabanas, H., et al., “Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome role in transient receptor potential melastatin 3 ion channels in pathophysiology and treatment,” *Front Immunol* 2021; 12:687806.
15. Albers, L., et al., “Treatment of Hailey-Hailey disease with low-dose naltrexone,” *JAMA Dermatol* 2017; 153(10):1018-20.
16. Ekelem, C., et al., “Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review,” *AMA Dermatol* 2019; 155(2):229-36.
17. Jaros, J., et al., “Low-dose naltrexone in dermatology,” *Jour Drugs Dermatol* 2019; 18(3):235-38.
18. Fretch, T., et al., “Low-dose naltrexone for pruritus in systemic sclerosis,” *Int Jour Rheumatol* 2011; 2011:804296.
19. Kendice, I., et al., “In vitro evaluation of Naltrexone HCl 1% topical cream in XemaTop™ for psoriasis,” *Arch Dermatol Res* 2020; 312(2):145-54.

LDN: A Game Changer for Many Patients

References

20. Monasterio, E., "Low-dose naltrexone: An alternative treatment for erythrodermic psoriasis," *Cureus* 2019; 11(1):e3943.
21. Bridgman, A., et al., "Treatment of psoriasis vulgaris using low-dose naltrexone," *JAAD Case Rep* 2018; 4:827-29.
22. Saleh, D., et al., *Guttate Psoriasis. Stat Pearls (Internet)*. Treasure Island, FL: StatPearls Publishing, 2022.
23. Muller, G., et al., "Compounded low-dose naltrexone for the treatment of guttate psoriasis: A case report," *Int Jour Pharm Compounding* 2018; 22(4):270-78.
24. Habif, T., *Atopic Dermatitis in Clinical Dermatology 5th Ed.*, St. Louis: Mosby, 2010.
25. Malekzad, F., et al., "Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study," *Jour Eur Acad Dermatol Venereol* 2009; 23(8):948-50.
26. Bigliardi, P., et al., "Treatment of pruritus with topically applied opiate receptor antagonist," *Jour Amer Acad Derm* 2007; 56(6):979-88.
27. Miskoff, J., et al., "Low dose naltrexone and lung cancer: a case report and discussion," *Cureus* 2018; 10(7):e2924.
28. Li, Z., et al., "Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy," *Int Immunopharmacol* 2018; 61:178-84.
29. Liu, W., et al., "Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy," *Int Jour Oncol* 2016; 49(2):793-802.
30. Kariv, R., et al., "Low-dose naltrexone for the treatment of irritable bowel syndrome: a pilot study," *Dig Dis Sci* 2006; 51(12):2128-33.
31. *Ibid.*, Patten.
32. Gold, M., et al., "Naltrexone, opiate addiction, and endorphins," *Med Res Rev* 1982; 2(3):211-16.
33. Bihari, B., et al., "Low-dose naltrexone for normalizing immune system function," *Altern Ther Health Med* 2013;19(2):56-65.
34. Zagon, I., et al., "Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors," *Brain Res* 1989; 480(1-2):16-28.
35. Smith, J., et al., "Low-dose naltrexone therapy improves active Crohn's disease," *Amer Jour Gastroenterol* 2007; 102(4):820-28.
36. Gold, M., et al., "Naltrexone, opiate addiction, and endorphins," *Med Res Rev* 1982; 2:211-46.
37. Trofimovitch, C., et al., "Pharmacology update: Low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes," *Amer Jour Hosp Palliat Care* 2019; 36(10):907-12.
38. Liu, B., et al., "Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration: Dissociation from the involvement of opioid receptors," *Methods Mol Med* 2002; 79; 43-54.
39. Liu, B., et al., "Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia cocultures," *Neurosci* 2000; 97:749-56.
40. Czlonkowski, A., et al., "Peripheral mechanisms of opioid antinociception in inflammation: Involvement of cytokines," *Eur Jour Pharmacol* 1993; 242:229-35.
41. Younger, J., et al., "The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain," *Clin Rheumatol* 2014; 33(4):451-59.
42. Kim, P., et al., "Low-dose naltrexone for chronic pain: Update and systematic review," *Curr Pain Headache Rep* 2020; 24(10):64.
43. San-Emeterio, E., et al., "Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice," *Neurosci Lett* 2006; 403:276-79.
44. Hota, D., et al., "Off-label, low-dose naltrexone for refractory painful diabetic neuropathy," *Pain Med* 2016; 17(4):790-91.
45. Hutchinson, M., et al., "Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)," *Eur Jour Neurosci* 2008; 28(1):20-9.
46. Younger, J., et al., "Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study," *Pain Med* 2009; 10(4):663-72.

LDN: A Game Changer for Many Patients

References

47. Younger, J., et al., "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels," *Arthritis Rheum* 2013; 65(2):529–38.
48. Parkitny, L., et al., "Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia," *Biomedicines* 2017; 5(2):E16.
49. Ghai, B., et al., "Off-label, low-dose naltrexone for refractory chronic low back pain," *Pain Med* 2014; 15(5):883–84.
50. Chopra, P., et al., "Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN)," *Jour Neuroimmune Pharmacol* 2013; 8(3): 470-76.
51. Mischoulon, D., et al., "Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants," *Jour Affect Disord* 2017; 208:6–14.
52. Brown, N., et al., "Low-dose naltrexone for disease prevention and quality of life," *Med Hypotheses* 2009; 72(3):333–37.
53. Smith, J., et al., "Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial," *Dig Dis Sci* 2011; 56(7):2088–97.
54. Younger, J., et al., "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels," *Arthritis Rheum* 2013; 65(2):529–38.
55. Cree, B., et al., "Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis," *Ann Neurol* 2010; 68(2):145–50.
56. Davis, M., et al., "Oxycodone combined with opioid receptor antagonists: efficacy and safety," *Expert Opin Drug Saf* 2013; 12(3):389–402.
57. ldnresearchtrust.org
58. Furman, D., et al., "Chronic inflammation in the etiology of disease across the life span," *Nat Med* 2019; 25(12):1822-32.
59. Chiappetta, S., et al., "COVID-19 and the role of chronic inflammation in patients with obesity," *Int Jour Obes (Lond)* 2020; 44(8):1790-92.
60. Garcia, L., et al., "Immune response, inflammation, and the clinical spectrum of COVID-19," *Front Immunol* 2020; 11:1441.



Townsend Letter .. for Doctors .. for Patients .. For All
Working with 'you' for almost 40 years, but we can't do it without your help!

Marie Abidin • Patch Adams • Gordon Amis • Moaid Ali • Irene Allegor • Henry Allen • Robert Anderson • Nancy Appleton • Albert
L. ...
Get Involved
• Darl ... • Donald Brown • Mark Brudnak • Johannes Budwig • Graham Burdick • Stanislaw Burzynski • Harold Buttram •
Charles ... • Churchill Coleman • Nicholas Coleman • Joseph Campbell • Bill Cardon • Donald Carraway • John Carroll • H.R.

TownsendLetter.com/get-involved